- Home
- BNY vs AQST Comparison
BNY vs AQST Comparison
Compare BNY & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNY
- AQST
- Stock Information
- Founded
- BNY 2001
- AQST 2004
- Country
- BNY United States
- AQST United States
- Employees
- BNY N/A
- AQST N/A
- Industry
- BNY Trusts Except Educational Religious and Charitable
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- BNY Finance
- AQST Health Care
- Exchange
- BNY Nasdaq
- AQST Nasdaq
- Market Cap
- BNY 233.2M
- AQST 272.9M
- IPO Year
- BNY N/A
- AQST 2018
- Fundamental
- Price
- BNY $9.60
- AQST $4.02
- Analyst Decision
- BNY
- AQST Strong Buy
- Analyst Count
- BNY 0
- AQST 7
- Target Price
- BNY N/A
- AQST $11.29
- AVG Volume (30 Days)
- BNY 52.7K
- AQST 1.3M
- Earning Date
- BNY 01-01-0001
- AQST 08-05-2025
- Dividend Yield
- BNY 3.93%
- AQST N/A
- EPS Growth
- BNY N/A
- AQST N/A
- EPS
- BNY N/A
- AQST N/A
- Revenue
- BNY N/A
- AQST $54,228,000.00
- Revenue This Year
- BNY N/A
- AQST N/A
- Revenue Next Year
- BNY N/A
- AQST $45.71
- P/E Ratio
- BNY N/A
- AQST N/A
- Revenue Growth
- BNY N/A
- AQST 5.29
- 52 Week Low
- BNY $8.60
- AQST $2.12
- 52 Week High
- BNY $10.80
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- BNY 47.42
- AQST 73.02
- Support Level
- BNY $9.60
- AQST $3.62
- Resistance Level
- BNY $9.69
- AQST $4.19
- Average True Range (ATR)
- BNY 0.07
- AQST 0.19
- MACD
- BNY 0.00
- AQST 0.04
- Stochastic Oscillator
- BNY 31.25
- AQST 83.96
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.